ATP3 MenLoading...Age20-34-935-39-440-44045-49+350-54+655-59+860-64+1065-69+1170-74+1275-79+13Tot Chol<160 (4.9) & Age 20-790160-199 (5.9-5.3)& Age 70-790200-239 (5.3-6.2)& Age 70-790160-199 (4.9-5.3)& Age 60-69+1200-239 (5.3-6.2)& Age 60-69+1240-279 (6.2-7.3)& Age 70-79+1280+ (7.3+)& Age 70-79+1160-199 (4.9-5.3)& Age 50-59+2240-279 (6.2-7.3)& Age 60-69+2160-199 (4.9-5.3)& Age 40-49+3200-239 (5.3-6.2)& Age 50-59+3280+ (7.3+)& Age 60-69+3160-199 (4.9-5.3)& Age 20-39+4240-279 (6.2-7.3)& Age 50-59+4200-239 (5.3-6.2)& Age 40-49+5280+ (7.3+)& Age 50-59+5240-279 (6.2-7.3)& Age 40-49+6200-239 (5.3-6.2)& Age 20-39+7280+ (7.3+)& Age 40-49+8240-279 (6.2-7.3)& Age 20-39+9280+ (7.3+)& Age 20-39+11SmokerNonsmoker & Age 20-790Smoker & Age 60-79+1Smoker & Age 70-79+1Smoker & Age 50-59+3Smoker & Age 40-49+5Smoker & Age 20-39+8HDL60+ (1.6+)-150-59 (1.3-1.6)040-49 (1.0-1.3)+1<40 (1.0)+2Syst BP<1200120-129 & Untreated0120-129 & Treated+1130-139 & Untreated+1140-159 & Untreated+1130-139 & Treated+2140-159 & Treated+2160+ & Untreated+2160+ & Treated+3Indications for UseInsights & CautionsReferencesC. Ardern. Revised Adult Treatment Panel III Guidelines and Cardiovascular Disease Mortality in Men Attending a Preventive Medical Clinic. Circulation, 2005